Skip to main content

Immuneering Corp 10-Q for FY2026 Q3

Immuneering Corp (IMRX)

10-Q 2026-10-29 For: 2026-09-30
View Original
Added on October 29, 2026

About this 10-Q

Immuneering Corp filed this 10-Q on October 29, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Immuneering raised the MAPKeeper 301 enrollment target from 510 to approximately 570 patients, ahead of schedule, keeping topline data planned for mid-2028. Net loss was $54.9 million for the nine months ended September 30, 2026, with $166.1 million in cash, cash equivalents and marketable securities. Cash is now expected to fund operations into the fourth quarter of 2028, previously into 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$24.19M
compared with a net loss of $14.96M a year earlier
Diluted EPS
-$0.37
compared with -$0.38 a year earlier